OSLO, Norway--(BUSINESS WIRE)--Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S.

Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130 The study ...

Two randomized controlled trials, one comparative study, one multi-institutional registry study, and 10 most recent case-series studies were evaluated. The level of evidence was low in 13 of the 14 ...

This patient presented with a moderately differentiated adenocarcinoma of the sigmoid colon, and was found to have intra-abdominal dissemination at the time of surgical resection. Tumor nodules in the ...

Oncoinvent ASA, a clinical-stage biotech focused on radiopharmaceutical cancer therapies and developer of the radium-224-based candidate Radspherin for peritoneal carcinomatosis, continues to advance ...

Progressing to study Radspherin ® in the first-line treatment setting for ovarian cancer IND clearance is now obtained for both lead indications for Radspherin ® OSLO, Norway--(BUSINESS ...